SEAGEN INC.

(SGEN)
  Rapport
Geschatte realtime Cboe BZX  -  17/05 16:23:11 CEST
144.66 USD   +1.48%
16/05Amerikaanse aandelen beginnen week overwegend lager temidden van de zwakte van de Empire State Manufacturing
MT
16/05WALL STREET : Wall Street verliest stoom
AM
16/05WALL STREET : Verdeeld beeld Wall Street
AM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť SEAGEN INC.
16/05SEAGEN INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
16/05Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
BU
09/05SEAGEN INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/05Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
BU
28/04SEAGEN : Reports First Quarter 2022 Financial Results - Form 8-K
PU
28/04SEAGEN INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
28/04SEATTLE GENETICS : Q1 Earnings Snapshot
AQ
28/04Seagen Reports First Quarter 2022 Financial Results
BU
28/04Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of ..
BU
20/04Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support..
BU
15/04SEAGEN INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial S..
AQ
13/04European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or..
BU
08/04SEAGEN : Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo - Form 8-..
PU
08/04SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/04Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
BU
08/04Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug..
BU
07/04Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial R..
BU
11/03SEAGEN INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits..
AQ
01/03Seagen to Present at the Cowen 42nd Annual Health Care Conference
BU
28/02Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortum..
BU
14/02Astellas and Seagen Announce Initial Results of PADCEVģ (enfortumab vedotin-ejfv) in Pa..
PR
09/02SEAGEN INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
09/02SEATTLE GENETICS : Q4 Earnings Snapshot
AQ
09/02SEAGEN : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
PU
09/02Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
BU
08/02Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
BU
04/02Seagen Inc. - ADCETRIS Combination Significantly Improves Overall Survival in Newly Dia..
AQ
03/02ADCETRISģ Combination Significantly Improves Overall Survival in Newly Diagnosed Patien..
BU
01/02Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
BU
18/01Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pan..
BU
18/01Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2..
BU
2021Seagen to Present at the J.P. Morgan Healthcare Conference
BU
2021Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRISģ (brentuxi..
BU
2021Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSAģ (tucat..
BU
2021SEAGEN : Publishes Inaugural Corporate Responsibility Report
PU
2021SEAGEN : Material Event - Form 8-K
PU
2021SEAGEN INC. : Other Events (form 8-K)
AQ
2021Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cance..
BU
2021Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual M..
BU
2021Seagen to Highlight Multiple ADCETRISģ (brentuximab vedotin) Data Presentations at the ..
BU
2021Q3 2021 Earnings Call Corrected Transcript
PU
2021SEAGEN INC. Management's Discussion and Analysis of Financial Condition and Results of..
AQ
2021SEATTLE GENETICS : Q3 Earnings Snapshot
AQ
2021Seagen Reports Third Quarter 2021 Financial Results - Form 8-K
PU
2021SEAGEN INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021Seagen Reports Third Quarter 2021 Financial Results
BU
2021Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
2021SEAGEN : to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Re..
BU
2021ASTELLAS PHARMA : Japan's MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelia..
AQ
2021SEAGEN : Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSAģ (..
BU
2021SEAGEN : = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS..
PU
2021SEAGEN INC. : Completion of Acquisition or Disposition of Assets, Financial Statements and..
AQ
2021SEAGEN : Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin..
AQ
2021SEAGEN : Presentation (opens in new window)
PU
2021SEAGEN : and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-..
PU
2021SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021SEAGEN : to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss T..
BU
2021SEAGEN : and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin..
BU
2021SEAGEN : to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
BU
2021SEAGEN : to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2..
BU
2021SEAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021SEAGEN : and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for..
BU
2021SEAGEN : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
2021SEAGEN : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
2021SEATTLE GENETICS : Q2 Earnings Snapshot
AQ
2021SEAGEN INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021SEAGEN : Reports Second Quarter 2021 Financial Results
BU
2021SEAGEN INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021ASTELLAS PHARMA : U.S. FDA Grants Regular Approval and Expands Indication for PADCEV (enfo..
AQ
2021SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021SEAGEN : to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial R..
BU
2021SEAGEN INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial O..
AQ
2021SEAGEN : Announces Long-Term Results from TUKYSAģ (tucatinib) Pivotal Trial in Patients wi..
BU
2021SEAGEN : to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
BU
2021ASTELLAS PHARMA : and Seagen Announce Updated Results from Two Trials of PADCEV (enfortuma..
AQ
1  2  3  4  5  6  7  8  9  10Volgende
OfficiŽle publicaties